Literature DB >> 20032969

Repetitive self-grooming behavior in the BTBR mouse model of autism is blocked by the mGluR5 antagonist MPEP.

Jill L Silverman1, Seda S Tolu, Charlotte L Barkan, Jacqueline N Crawley.   

Abstract

Autism is a neurodevelopmental disorder characterized by abnormal reciprocal social interactions, communication deficits, and repetitive behaviors with restricted interests. BTBR T+tf/J (BTBR) is an inbred mouse strain that shows robust behavioral phenotypes with analogies to all three of the diagnostic symptoms of autism, including well-replicated deficits in reciprocal social interactions and social approach, unusual patterns of ultrasonic vocalization, and high levels of repetitive self-grooming. These phenotypes offer straightforward behavioral assays for translational investigations of pharmacological compounds. Two suggested treatments for autism were evaluated in the BTBR mouse model. Methyl-6-phenylethynyl-pyridine (MPEP), an antagonist of the mGluR5 metabotropic glutamate receptor, blocks aberrant phenotypes in the Fmr1 mouse model of Fragile X, a comorbid neurodevelopmental disorder with autistic features. Risperidone has been approved by the United States Food and Drug Administration for the treatment of irritability, tantrums, and self-injurious behavior in autistic individuals. We evaluated the actions of MPEP and risperidone on two BTBR phenotypes, low sociability and high repetitive self-grooming. Open field activity served as an independent control for non-social exploratory activity and motor functions. C57BL/6J (B6), an inbred strain with high sociability and low self-grooming, served as the strain control. MPEP significantly reduced repetitive self-grooming in BTBR, at doses that had no sedating effects on open field activity. Risperidone reduced repetitive self-grooming in BTBR, but only at doses that induced sedation in both strains. No overall improvements in sociability were detected in BTBR after treatment with either MPEP or risperidone. Our findings suggest that antagonists of mGluR5 receptors may have selective therapeutic efficacy in treating repetitive behaviors in autism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20032969      PMCID: PMC2827881          DOI: 10.1038/npp.2009.201

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  108 in total

Review 1.  The developmental neurobiology of autism spectrum disorder.

Authors:  Emanuel DiCicco-Bloom; Catherine Lord; Lonnie Zwaigenbaum; Eric Courchesne; Stephen R Dager; Christoph Schmitz; Robert T Schultz; Jacqueline Crawley; Larry J Young
Journal:  J Neurosci       Date:  2006-06-28       Impact factor: 6.167

Review 2.  Social skills development in children with autism spectrum disorders: a review of the intervention research.

Authors:  Susan Williams White; Kathleen Keonig; Lawrence Scahill
Journal:  J Autism Dev Disord       Date:  2006-12-29

Review 3.  Animal models of restricted repetitive behavior in autism.

Authors:  Mark H Lewis; Yoko Tanimura; Linda W Lee; James W Bodfish
Journal:  Behav Brain Res       Date:  2006-09-25       Impact factor: 3.332

4.  Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.

Authors:  Gary E Duncan; Sheryl S Moy; Jeffrey A Lieberman; Beverly H Koller
Journal:  Pharmacol Biochem Behav       Date:  2006-11-13       Impact factor: 3.533

5.  Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice.

Authors:  Liesbeth A Bruins Slot; Laurent Bardin; Agnès L Auclair; Ronan Depoortere; Adrian Newman-Tancredi
Journal:  Behav Pharmacol       Date:  2008-03       Impact factor: 2.293

6.  Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function.

Authors:  Lynsey Meikle; Kristen Pollizzi; Anna Egnor; Ioannis Kramvis; Heidi Lane; Mustafa Sahin; David J Kwiatkowski
Journal:  J Neurosci       Date:  2008-05-21       Impact factor: 6.167

Review 7.  Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability.

Authors:  Mihir S Parikh; Alexander Kolevzon; Eric Hollander
Journal:  J Child Adolesc Psychopharmacol       Date:  2008-04       Impact factor: 2.576

Review 8.  A synaptic trek to autism.

Authors:  Thomas Bourgeron
Journal:  Curr Opin Neurobiol       Date:  2009-06-21       Impact factor: 6.627

Review 9.  Diagnosis of autism spectrum disorders in the first 3 years of life.

Authors:  Rebecca J Landa
Journal:  Nat Clin Pract Neurol       Date:  2008-02-05

Review 10.  Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist.

Authors:  C Lintas; A M Persico
Journal:  J Med Genet       Date:  2008-08-26       Impact factor: 6.318

View more
  171 in total

1.  Social peers rescue autism-relevant sociability deficits in adolescent mice.

Authors:  Mu Yang; Kayla Perry; Michael D Weber; Adam M Katz; Jacqueline N Crawley
Journal:  Autism Res       Date:  2010-10-06       Impact factor: 5.216

Review 2.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

3.  Mainstreaming mice.

Authors:  Brooke A Babineau; Mu Yang; Jacqueline N Crawley
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

4.  Association of mouse Dlg4 (PSD-95) gene deletion and human DLG4 gene variation with phenotypes relevant to autism spectrum disorders and Williams' syndrome.

Authors:  Michael Feyder; Rose-Marie Karlsson; Poonam Mathur; Matthew Lyman; Roland Bock; Reza Momenan; Jeeva Munasinghe; Maria Luisa Scattoni; Jessica Ihne; Marguerite Camp; Carolyn Graybeal; Douglas Strathdee; Alison Begg; Veronica A Alvarez; Peter Kirsch; Marcella Rietschel; Sven Cichon; Henrik Walter; Andreas Meyer-Lindenberg; Seth G N Grant; Andrew Holmes
Journal:  Am J Psychiatry       Date:  2010-10-15       Impact factor: 18.112

5.  Density and function of central serotonin (5-HT) transporters, 5-HT1A and 5-HT2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior.

Authors:  Georgianna G Gould; Julie G Hensler; Teresa F Burke; Robert H Benno; Emmanuel S Onaivi; Lynette C Daws
Journal:  J Neurochem       Date:  2010-12-02       Impact factor: 5.372

6.  Insulin-Like Growth Factor II Targets the mTOR Pathway to Reverse Autism-Like Phenotypes in Mice.

Authors:  Adam B Steinmetz; Sarah A Stern; Amy S Kohtz; Giannina Descalzi; Cristina M Alberini
Journal:  J Neurosci       Date:  2017-12-07       Impact factor: 6.167

7.  Somatosensorimotor and Odor Modification, Along with Serotonergic Processes Underlying the Social Deficits in BTBR T+ Itpr3tf/J and BALB/cJ Mouse Models of Autism.

Authors:  Hiroyuki Arakawa
Journal:  Neuroscience       Date:  2020-02-13       Impact factor: 3.590

Review 8.  Advancing the discovery of medications for autism spectrum disorder using new technologies to reveal social brain circuitry in rodents.

Authors:  Martien J Kas; Meera E Modi; Michael D Saxe; Daniel G Smith
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

9.  Parvalbumin cell ablation of NMDA-R1 causes increased resting network excitability with associated social and self-care deficits.

Authors:  Eddie N Billingslea; Valerie M Tatard-Leitman; Jaynie Anguiano; Catherine R Jutzeler; Jimmy Suh; John A Saunders; Susumu Morita; Robert E Featherstone; Pavel I Ortinski; Michael J Gandal; Robert Lin; Yuling Liang; Raquel E Gur; Gregory C Carlson; Chang-Gyu Hahn; Steven J Siegel
Journal:  Neuropsychopharmacology       Date:  2014-02-14       Impact factor: 7.853

10.  Repetitive behavior profile and supersensitivity to amphetamine in the C58/J mouse model of autism.

Authors:  Sheryl S Moy; Natallia V Riddick; Viktoriya D Nikolova; Brian L Teng; Kara L Agster; Randal J Nonneman; Nancy B Young; Lorinda K Baker; Jessica J Nadler; James W Bodfish
Journal:  Behav Brain Res       Date:  2013-11-08       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.